Pompe Disease

Pompe disease is a rare inherited disorder caused by pathogenic variants affecting acid alpha-glucosidase, leading to glycogen accumulation in muscle cells. Clinical presentation varies from rapidly progressive infantile-onset disease to later-onset forms involving skeletal, respiratory, and sometimes cardiac muscle. Diagnosis and management require coordinated genetic, biochemical, neurologic, respiratory, cardiac, and rehabilitation expertise.

Care pathways are increasingly shaped by earlier recognition, confirmatory enzyme and molecular testing, multidisciplinary assessment, and longitudinal monitoring of motor, respiratory, cardiac, nutritional, and functional outcomes. Newborn screening and improved awareness can shorten diagnostic delays, while home-based support, respiratory services, physical therapy, and patient-reported outcomes are becoming more important complements to specialist treatment. Persistent challenges include variable disease expression, delayed diagnosis in late-onset cases, treatment access, immune response management, and continuity of care across life stages.

Artificial intelligence can support Pompe disease care by identifying diagnostic signals in electronic records, laboratory data, imaging, respiratory assessments, and genetic information. Machine-learning tools may help prioritize individuals for confirmatory testing, distinguish disease patterns from other neuromuscular conditions, and detect changes in functional or respiratory status. Its practical value will depend on representative datasets, transparent validation, clinician oversight, privacy safeguards, and careful management of false positives and underdiagnosis in populations that are less well represented in research.

North America benefits from specialized neuromuscular centers, genetic testing capacity, and established multidisciplinary care, although coverage rules and geographic access remain consequential. Europe combines strong clinical expertise with cross-border variation in screening, reimbursement, and treatment pathways. Asia-Pacific includes advanced diagnostic systems alongside substantial differences in specialist availability, public awareness, and access across countries. Latin America faces diagnostic and referral gaps, with care concentrated in major urban centers. The Middle East is developing rare-disease infrastructure while navigating uneven testing capacity and specialist distribution. Africa continues to face limited recognition, confirmatory testing, and access to specialized management, making regional networks and capacity building especially important.

ASEAN countries show varied rare-disease policies, laboratory capacity, and referral networks, creating opportunities for shared protocols and cross-border expertise. BRICS members span substantial differences in screening, reimbursement, registries, and specialist access, making national implementation conditions critical. The European Union benefits from collaborative regulatory and research structures, but national health-system decisions still shape availability and continuity of care. G7 systems generally possess advanced diagnostic and clinical infrastructure, while affordability and equitable access remain priorities. GCC countries are strengthening specialized healthcare and genomic capabilities, with coordinated referral models supporting earlier diagnosis. NATO countries collectively include diverse health systems, so collaboration in preparedness and research does not remove differences in Pompe disease service delivery.

Australia has established rare-disease and neuromuscular expertise, with access influenced by geography and specialist concentration. Brazil and Mexico continue working through regional disparities in diagnosis and treatment access. Canada and the United States have specialized centers and advanced testing, while coverage and distance can affect continuity. China and India are expanding genomic and specialist capacity but face major differences between urban and rural services. France, Germany, Italy, Spain, and the United Kingdom have substantial clinical expertise, with national pathways, screening practices, and reimbursement arrangements varying across systems. Japan and South Korea combine advanced healthcare infrastructure with continued needs for awareness and timely recognition. Russia’s access landscape is shaped by regional infrastructure and availability of specialized services.

Industry leaders should support validated diagnostic algorithms, clinician education, and referral pathways that connect primary care with neuromuscular specialists. Investment should focus on interoperable registries, longitudinal outcome measurement, newborn-screening evaluation where appropriate, and evidence generation for diverse patient populations. Care models should integrate respiratory, cardiac, motor, nutritional, genetic, psychosocial, and rehabilitation services. Organizations developing digital or artificial-intelligence tools should use transparent validation, human oversight, and privacy-preserving governance. Partnerships with patient communities and health systems can help identify access barriers, improve adherence, and align innovation with meaningful functional outcomes.

This executive summary uses a structured review approach focused on verified information about Pompe disease biology, diagnosis, clinical management, care delivery, and health-system access. Findings are synthesized from authoritative clinical guidance, peer-reviewed literature, public health and regulatory materials, rare-disease organizations, and documented regional or national health-system information. Claims were screened for relevance and consistency, while unsupported numerical estimates, market metrics, forecasts, and company-specific assertions were excluded. Regional, group, and country observations are presented as qualitative comparisons because diagnostic capacity, policy, and access can vary within each geography.

Pompe disease management is advancing through better recognition, confirmatory testing, multidisciplinary care, and increasingly data-enabled monitoring. The central opportunity is to translate scientific and clinical progress into earlier diagnosis and sustained access across different health systems and life stages. Leaders should combine diagnostic capacity building, coordinated care, responsible artificial intelligence, outcome tracking, and patient-centered policy to improve functional, respiratory, cardiac, and quality-of-life outcomes.